Boehringer
Jardiance scores more cardiovascular outcomes data
November 10, 2015Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes
A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …
Lilly and Boehringer launch biosimilar insulin in the UK
August 26, 2015Manufacturing and Production, Research and Development, Sales and Marketing Boehringer, Boehringer Ingelheim, Eli Lilly, Lantus, abasaglar, basal insulin, biosimilar, biosimilars, diabetes, insuling glargine, lilly
Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar will now challenge the …
Boehringer and Vitae Pharma drug fails in mid-stage trial
July 1, 2015Research and Development BI, Boehringer, Boehringer Ingelheim, Vitae Pharmaceuticals, diabetes, type 2 diabetes
A pipeline diabetes drug co-developed by Vitae Pharma and German giants Boehringer Ingelheim has failed to show benefits in a …
Boehringer scores trial success for Pradaxa antidote
June 29, 2015Research and Development, Sales and Marketing Boehringer, Pradaxa, idarucizumab
Bosses at Boehringer Ingelheim say the latest results of a study of idarucizumab, and antidote for its blockbuster blood-thinner Pradaxa, …
Boehringer and Eureka reach cancer antibodies deal
May 22, 2015Research and Development, Sales and Marketing Boehringer, eureka
Boehringer Ingelheim and Eureka Therapeutics have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology.No …
FDA issues more diabetes drug warnings
May 18, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Boehringer, J&J, JJ, lilly
The FDA has warned that a class of type 2 diabetes drugs manufactured by several big pharma firms could cause …
Boehringer widens IPF drug’s reach
May 18, 2015Sales and Marketing Boehringer, Esbriet, ats, brett wells, nintedanib, ofev
Boehringer Ingelheim has highlighted new data for its idiopathic pulmonary fibrosis (IPF) treatment Ofev in a Phase II study on …
Boehringer assures future growth following sales drop
April 23, 2015Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results
Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …
Sanofi rules out Toujeo discount in diabetes
April 14, 2015Sales and Marketing 100 U/mL, Boehringer, Lantus, insulin glargine [rDNA origin] injection, lilly, toujeo
Sanofi has revealed that it will not discount its new insulin Toujeo more than its current blockbuster Lantus, despite lacking …
EMA committee recommends five drugs for approval
March 30, 2015Sales and Marketing Boehringer, CHMP, EMA, Eisai, Europe, Gardasil, Lenvima, Merck, akynzio, jardiance, lilly
Cancer and diabetes treatments are among those given the go ahead in the latest round of approvals by the EMA. …
NICE decisions made on Bayer, Celgene and Boehringer drugs
March 26, 2015Sales and Marketing Bayer, Boehringer, Celgene, NHS, Xarelto, imnovid, jardiance
In final guidance NICE has recommended Bayer’s Xarelto and Boehringer’s Jardiance for NHS funding, but not Celgene’s Imnovid. Bayer’s Xarelto …
Lilly and Boehringer diabetes drug sees US launch
March 24, 2015Sales and Marketing Boehringer, Glyxambi, Tradjenta, diabetes, empagliflozin/linagliptin, lilly, linagliptin
Lilly and Boehringer Ingelheim’s combo diabetes drug Glyxambi is now available to treat adult patients in the US. Glyxambi (empagliflozin/linagliptin) …
Boehringer eyes Ofev success in IPF and beyond
March 16, 2015Sales and Marketing Boehringer, Esbriet, Roche, ingelheim, inpulsis, ipd, ofev
Experts say the launch of Boehringer Ingelheim’s new treatment for idiopathic pulmonary fibrosis (IPF) offers stiff competition to Roche’s Esbriet …
Boehringer chases approval for anti-Pradaxa drug
March 3, 2015Sales and Marketing Boehringer, Boehringer Ingelheim, Pradaxa, bleeding, dabigatran etexilate, idarucizumab
Boehringer Ingelheim is launching new drug applications for its investigational treatment to reverse the effects of its blood-thinning drug Pradaxa. …
Boehringer’s beer breach at German congress
February 20, 2015Medical Communications, Sales and Marketing ABPI, Boehringer, ERS, IPF, PMCPA, breach, code, munich
A complaint made by a pulmonologist against the competence of Boehringer Ingelheim speakers during a congress held in Germany last …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
